Metiamide

DB08805

small molecule experimental

Deskripsi

Metiamide is an H-2 receptor antagonist derived from burimamide. It was an intermediate product on the path to developing cimetidine.

Struktur Molekul 2D

Berat 244.38
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

119 Data
Atazanavir Metiamide can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cefditoren The serum concentration of Cefditoren can be decreased when it is combined with Metiamide.
Dabigatran etexilate Metiamide can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Dabrafenib Metiamide can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Erlotinib Metiamide can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Pazopanib Metiamide can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Riociguat Metiamide can cause a decrease in the absorption of Riociguat resulting in a reduced serum concentration and potentially a decrease in efficacy.
Benzylpenicilloyl polylysine Metiamide may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent.
Betahistine The therapeutic efficacy of Betahistine can be decreased when used in combination with Metiamide.
Hyaluronidase (ovine) The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Metiamide.
Hyaluronidase (human recombinant) The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Metiamide.
Hyaluronidase The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Metiamide.
Bosutinib Metiamide can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cefpodoxime Metiamide can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cefuroxime Metiamide can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy.
Dasatinib Metiamide can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Delavirdine Metiamide can cause a decrease in the absorption of Delavirdine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Dexmethylphenidate The therapeutic efficacy of Dexmethylphenidate can be decreased when used in combination with Metiamide.
Amprenavir Metiamide can cause a decrease in the absorption of Amprenavir resulting in a reduced serum concentration and potentially a decrease in efficacy.
Fosamprenavir Metiamide can cause a decrease in the absorption of Fosamprenavir resulting in a reduced serum concentration and potentially a decrease in efficacy.
Gefitinib Metiamide can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Indinavir Metiamide can cause a decrease in the absorption of Indinavir resulting in a reduced serum concentration and potentially a decrease in efficacy.
Itraconazole Metiamide can cause a decrease in the absorption of Itraconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ledipasvir Metiamide can cause a decrease in the absorption of Ledipasvir resulting in a reduced serum concentration and potentially a decrease in efficacy.
Methylphenidate The therapeutic efficacy of Methylphenidate can be decreased when used in combination with Metiamide.
Nelfinavir Metiamide can cause a decrease in the absorption of Nelfinavir resulting in a reduced serum concentration and potentially a decrease in efficacy.
Nilotinib Metiamide can cause a decrease in the absorption of Nilotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Rilpivirine Metiamide can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Risedronic acid Metiamide can cause an increase in the absorption of Risedronic acid resulting in an increased serum concentration and potentially a worsening of adverse effects.
Saquinavir Metiamide can cause an increase in the absorption of Saquinavir resulting in an increased serum concentration and potentially a worsening of adverse effects.
Levothyroxine Metiamide can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Bisacodyl The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Metiamide.
Captopril Metiamide can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy.
Rifampin Metiamide can cause a decrease in the absorption of Rifampicin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Memantine Metiamide may decrease the excretion rate of Memantine which could result in a higher serum level.
Sulpiride The therapeutic efficacy of Sulpiride can be increased when used in combination with Metiamide.
Mesalazine Metiamide can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Mycophenolate mofetil Metiamide can cause a decrease in the absorption of Mycophenolate mofetil resulting in a reduced serum concentration and potentially a decrease in efficacy.
Mycophenolic acid Metiamide can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Tolevamer The therapeutic efficacy of Tolevamer can be decreased when used in combination with Metiamide.
Amphetamine Amphetamine may decrease the sedative activities of Metiamide.
Phentermine Phentermine may decrease the sedative activities of Metiamide.
Pseudoephedrine Pseudoephedrine may decrease the sedative activities of Metiamide.
Benzphetamine Benzphetamine may decrease the sedative activities of Metiamide.
Diethylpropion Diethylpropion may decrease the sedative activities of Metiamide.
Lisdexamfetamine Lisdexamfetamine may decrease the sedative activities of Metiamide.
Mephentermine Mephentermine may decrease the sedative activities of Metiamide.
MMDA MMDA may decrease the sedative activities of Metiamide.
Midomafetamine Midomafetamine may decrease the sedative activities of Metiamide.
2,5-Dimethoxy-4-ethylamphetamine 2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Metiamide.
4-Bromo-2,5-dimethoxyamphetamine 4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Metiamide.
Tenamfetamine Tenamfetamine may decrease the sedative activities of Metiamide.
Chlorphentermine Chlorphentermine may decrease the sedative activities of Metiamide.
Methylenedioxyethamphetamine Methylenedioxyethamphetamine may decrease the sedative activities of Metiamide.
Dextroamphetamine Dextroamphetamine may decrease the sedative activities of Metiamide.
Metamfetamine Metamfetamine may decrease the sedative activities of Metiamide.
Iofetamine I-123 Iofetamine I-123 may decrease the sedative activities of Metiamide.
Ritobegron Ritobegron may decrease the sedative activities of Metiamide.
Mephedrone Mephedrone may decrease the sedative activities of Metiamide.
Methoxyphenamine Methoxyphenamine may decrease the sedative activities of Metiamide.
Gepefrine Gepefrine may decrease the sedative activities of Metiamide.
2,5-Dimethoxy-4-ethylthioamphetamine 2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Metiamide.
Phendimetrazine Phendimetrazine may decrease the sedative activities of Metiamide.
Cysteamine The bioavailability of Cysteamine can be decreased when combined with Metiamide.
Ketoconazole Metiamide can cause a decrease in the absorption of Ketoconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.
Methenamine The therapeutic efficacy of Methenamine can be decreased when used in combination with Metiamide.
Iron Dextran Metiamide can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.
Iron Metiamide can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferric pyrophosphate Metiamide can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Prussian blue Metiamide can cause a decrease in the absorption of Prussian blue resulting in a reduced serum concentration and potentially a decrease in efficacy.
Iron sucrose Metiamide can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferric ammonium citrate Metiamide can cause a decrease in the absorption of Ferric ammonium citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferumoxsil Metiamide can cause a decrease in the absorption of Ferumoxsil resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferumoxides Metiamide can cause a decrease in the absorption of Ferumoxides resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferric sulfate Metiamide can cause a decrease in the absorption of Ferric sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferrous bisglycinate Metiamide can cause a decrease in the absorption of Ferrous bisglycinate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Gleptoferron Metiamide can cause a decrease in the absorption of Gleptoferron resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferric oxide Metiamide can cause a decrease in the absorption of Ferric oxide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Perflubutane Metiamide can cause a decrease in the absorption of Perflubutane resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferrous sulfate anhydrous Metiamide can cause a decrease in the absorption of Ferrous sulfate anhydrous resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sodium feredetate Metiamide can cause a decrease in the absorption of Sodium feredetate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferric hydroxide Metiamide can cause a decrease in the absorption of Ferric hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferric cation Metiamide can cause a decrease in the absorption of Ferric cation resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferrous gluconate Metiamide can cause a decrease in the absorption of Ferrous gluconate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferrous succinate Metiamide can cause a decrease in the absorption of Ferrous succinate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferrous fumarate Metiamide can cause a decrease in the absorption of Ferrous fumarate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Tetraferric tricitrate decahydrate Metiamide can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferric oxyhydroxide Metiamide can cause a decrease in the absorption of Ferric oxyhydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferric maltol Metiamide can cause a decrease in the absorption of Ferric maltol resulting in a reduced serum concentration and potentially a decrease in efficacy.
Iron polymaltose Metiamide can cause a decrease in the absorption of Iron polymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.
Fluconazole Metiamide can cause a decrease in the absorption of Fluconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.
Voriconazole Metiamide can cause a decrease in the absorption of Voriconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.
Miconazole Metiamide can cause a decrease in the absorption of Miconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.
Posaconazole Metiamide can cause a decrease in the absorption of Posaconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.
Abafungin Metiamide can cause a decrease in the absorption of Abafungin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ravuconazole Metiamide can cause a decrease in the absorption of Ravuconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.
Isavuconazonium Metiamide can cause a decrease in the absorption of Isavuconazonium resulting in a reduced serum concentration and potentially a decrease in efficacy.
Isavuconazole Metiamide can cause a decrease in the absorption of Isavuconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.
Albaconazole Metiamide can cause a decrease in the absorption of Albaconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.
Bifonazole Metiamide can cause a decrease in the absorption of Bifonazole resulting in a reduced serum concentration and potentially a decrease in efficacy.

Target Protein

Histamine H2 receptor HRH2

Referensi & Sumber

Belum ada data referensi/link/attachment untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field referensi.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul